Market Newsdesk

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) — Atlantic.Net Inc., a global cloud services provider, replaced or integrated more than 50 different subscription billing, device management and customer support systems into one. Ubersmith business management software has improved business processes from seven to 14 days to one day, quickened response to support issues by enabling resolution in half of the previous time and realized a 55% improvement in billing for customers’ overage usage.

“By consolidating all our previous systems into Ubersmith, customer information related to billing, products and service is centralized in one place, making it readily accessible,” said Marty Puranik, founder and CEO, Atlantic.Net. “Plus, we’ve eliminated the need for training our staff on different systems, which saves countless hours and streamlines resources.”

“We can automatically tie support tickets to information about specific devices and customers, and as a result, our support ticket times have dropped in half,” said Puranik. “Also, we have better capabilities to monitor customer usage and bill accordingly, which is a net positive for revenue growth.”

Atlantic.Net has achieved tremendous operational efficiencies and substantial cost savings by eliminating many redundant systems.

Started in 1994 in Gainesville, Florida, Atlantic.Net quickly expanded to other cities with new office openings and acquisitions of service providers. Today, it operates out of five data centers in the U.S., one in Canada, and one in the U.K., with plans to expand services in Amsterdam and Singapore next year. Atlantic.Net is a global cloud services provider, providing more than 15,000 customers with business-class dedicated and cloud hosting solutions backed by 24/7/365 support.

Ubersmith is an easily customizable, integrated, and modular software suite for subscription billing, quoting, order management, infrastructure management and ticketing. A plug-in system provides flexibility for extending and integrating other software used as part of business operations. Ubersmith provides an application programming interface (API) and software development kit (SDK) to enable customers and partners to easily integrate other systems and programs with the Ubersmith suite.

“We make extensive use of Ubersmith APIs to integrate with other systems that we use for payments, accounting, domain registration, security certificates and more,” said Puranik.

Deep integrations with the Ubersmith software enable Atlantic.Net to achieve high levels of efficiency in operations, helping to improve employee productivity and ultimately provide higher levels of customer service. Atlantic.Net is known for delivering outstanding products, service and high customer satisfaction with one of the lower customer churn rates in the VPS hosting industry.

With Ubersmith’s plans to soon add support for Salesforce, Atlantic.Net will be able to tie in its sales and prospecting activities, along with customer quotes, in its systems.

“Atlantic.Net has done an impressive job at leveraging the capabilities we provide in Ubersmith’s business management, infrastructure and operations software,” said Kurt Daniel, CEO of Ubersmith. “We’re pleased to be an important partner for their business as they continue to grow and expand in the cloud services and hosting arenas.”

About Atlantic.Net

Atlantic.Net is a global cloud services provider with over 25 years of experience, specializing in managed and non-managed Windows, Linux, and FreeBSD server hosting solutions and HIPAA compliant hosting. With a focus on security, compliance, and simplifying the user experience, Atlantic.Net provides business-class dedicated and cloud hosting solutions, backed by 24/7/365 support through their global data centers located in New York, London, San Francisco, Toronto, Dallas, Ashburn, and Orlando. For more information, please visit https://www.atlantic.net.

About Ubersmith

Ubersmith is a leader in subscription management software for the cloud and beyond. Headquartered in New York, Ubersmith provides billing, infrastructure and ticketing solutions that are open, scalable, and integrated. Organizations worldwide rely on Ubersmith to better serve their customers and better run their businesses. For more, please visit https://ubersmith.com.

Glenn Rossman
(914) 623-8354
[email protected]

MINNEAPOLIS, Dec. 08, 2020 (GLOBE NEWSWIRE) —  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has completed patient enrollment in its Phase 1 trial evaluating the safety and tolerability of SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA). 

The trial, which included a dose escalation phase and an expansion phase, enrolled 50 patients, 30 of whom were treated using the dose and schedule that will advance to a randomized trial of the combination versus gemcitabine and nab-paclitaxel alone planned to begin in the first half of 2021.  In total, the safety of SBP-101 has been evaluated in 79 patients in two clinical trials.

“We are pleased to have completed enrollment in our Phase 1b trial and expect to announce data in the first half of next year,” commented Jennifer Simpson, PhD., M.S.N., C.R.N.P.  – President & Chief Executive Officer.  “Completing enrollment for SBP-101 marks an important milestone in our quest to bring new therapeutic options to patients with pancreatic cancer, which is an orphan disease and an area of unmet medical need.”

SBP-101 is currently being evaluated in a Phase 1a/1b clinical trial of patients with previously untreated metastatic PDA at sites in the United States and Australia. SBP -101 has received Fast Track and orphan drug designation from FDA.  For more information, please visit clinicaltrials.gov.

About SBP-101 

SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting complementary activity with an existing FDA-approved chemotherapy regimen. In clinical studies to date, SBP-101 has not shown exacerbation of the typical chemotherapy-related adverse events of bone marrow suppression and peripheral neuropathy. The safety data and PMI profile observed in the current Panbela sponsored current clinical trial provides support for continued evaluation of the compound in a randomized clinical trial.  For more information, please visit https://clinicaltrials.gov/ct2/show/NCT03412799.

About Panbela Therapeutics, Inc

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company’s initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. is dedicated to treating patients with pancreatic cancer and exploring SBP-101’s potential for efficacy in combination with other agents and in treating other types of cancer. Further information can be found at: www.panbela.com. Panbela Therapeutics, Inc. common stock is listed on The Nasdaq Stock Market LLC under the symbol PBLA. 

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements,” including within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “believes,” “ dedicated,” “expects,” “intends,” “may,” “milestone,” or “plans.” Examples of forward-looking statements include, among others, statements we make regarding, potential effects of FDA Fast Track designation, future determinations of the characteristics of SBP-101 and its effectiveness, uses of proceeds from recent financings. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially and adversely from the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) our ability to obtain additional funding to complete a randomized clinical trial; (ii) progress and success of our Phase 1 clinical trial; (iii) the impact of the current COVID-19 pandemic on our ability to complete monitoring and reporting in our current clinical trial; (iv) our ability to demonstrate the safety and effectiveness of our SBP-101 product candidate (v) our ability to obtain regulatory approvals for our SBP-101 product candidate in the United States, the European Union or other international markets; (vi) the market acceptance and level of future sales of our SBP-101 product candidate; (vii) the cost and delays in product development that may result from changes in regulatory oversight applicable to our SBP-101 product candidate; (viii) the rate of progress in establishing reimbursement arrangements with third-party payors; (ix) the effect of competing technological and market developments; (x) the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims; and (xi) such other factors as discussed in Part I, Item 1A under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, any additional risks presented in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Any forward-looking statement made by us in this press release is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement or reasons why actual results would differ from those anticipated in any such forward-looking statement, whether written or oral, whether as a result of new information, future developments or otherwise.

Contact Information:

Investors: 
James Carbonara 
Hayden IR 
(646) 755-7412 
[email protected]

Media: 
Tammy Groene 
Panbela Therapeutics, Inc. 
(952) 479-1196 
[email protected]

BASKING RIDGE, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today top-line results from its GM-US-10 (PREMIUM II) study. Despite the early termination of the study in April 2020 due to the COVID-19 pandemic, all study endpoints, including several patient-assessed quality of life measures, showed benefit from non-invasive vagus nerve stimulation (nVNS), with many endpoints showing a statistically significant improvement with nVNS compared to sham stimulation.

In the predefined modified intent to treat population (mITT; n=113), which was the designated primary analysis population for the study, patients using gammaCore™ nVNS had 3.1 less migraine days over the final four weeks of the 12 week double blind study period versus the four weeks of the run-in period as compared to a decrease of 2.3 migraine days in the sham group (primary endpoint; p=0.233).

Within the mITT population, 44.9% of the subjects using gammaCore™ nVNS had at least a 50% decrease in the number of migraine days compared to 26.8% for those receiving sham stimulation (secondary endpoint; p=0.048). Patients using gammaCore also reported a statistically significant decrease in migraine associated disability and improvement in their quality of life across all of the quality of life (QOL) endpoints in the study.

Of particular interest were the results in the predefined sub-population of patients diagnosed as having migraine with aura. In this group, patients using nVNS had 5.5 fewer headache days compared to 2.7 fewer headache days in the sham group (p=0.041). There were no serious adverse effects reported in the study, which is consistent with nVNS’ strong safety and tolerability profile.

Complete results of the study are expected to be published in early 2021 in a peer reviewed neurology journal. gammaCore™ received 510(k) clearance for the preventative treatment of migraine on March 26, 2020.

Dr. Umer Najib, MD, FAHS, Director of the West Virginia University Headache Center and an investigator in the PREMIUM II study, commented “I am pleased that nVNS continues to demonstrate its ability to effectively decrease the migraine burden in patients who need preventive therapy. The strong benefit seen in patients diagnosed with aura is particularly interesting as those patients can often be particularly difficult to treat.”

“The results of the PREMIUM II study highlight the unique role gammaCore nVNS can play as the only headache treatment that has demonstrated an ability to decrease the number of migraine days a patient experiences while also being able to treat the acute pain of migraines that occur in spite of a preventive regimen,” said Eric Liebler, SVP of Neurology at electroCore, Inc. “Although the ongoing COVID-19 pandemic negatively impacted our ability to fully enroll PREMIUM II, our analysis indicates we likely would have reached statistical significance on all of our predefined endpoints had the study reached its original enrollment targets. With FDA clearances for the acute and preventive treatment of both cluster and migraine headache, gammaCore continues to differentiate itself as one of the most effective, safe and flexible treatments available to help patients looking for a way to take control of their headache treatment.”

PREMIUM II was a randomized, double-blind, sham-controlled clinical trial of gammaCore™ for the prevention of migraine conducted at over 30 sites in the United States (ClinicalTrials.gov identifier NCT03716505). The study was originally designed based on mITT of approximately 300 subjects. The study was closed before reaching its original enrollment targets in Q2 of 2020 due to the impact of COVID-19 on the conduct of clinical trials, resulting in intent to treat (ITT) and mITT groups of 228 and 113, respectively.

About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCore
^TM
gammaCore^TM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. 

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

• Safety and efficacy of gammaCore have not been evaluated in the following patients:
  • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  • Pediatric patients
  • Pregnant women
  • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
• Patients should not use gammaCore if they:
  • Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  • Have a metallic device such as a stent, bone plate, or bone screw implanted at or near their neck
  • Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

In the US, the FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders such as acute respiratory stress disorder associated with COVID-19.

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the expected date of publication of complete study results from the PREMIUM II trial and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.

Investors:

Hans Vitzthum
LifeSci Advisors
617-430-7578
[email protected]

or

Media Contact:

Jackie Dorsky
electroCore
973-290-0097
[email protected]

New York, Dec. 08, 2020 (GLOBE NEWSWIRE) — Vincent, an online platform that helps investors gain access to alternative assets, today announced the launch of a search engine where investors can discover and diligence hundreds of alternative investment opportunities from more than 50 partnering investment platforms. 

Online investing, like much of fintech, has recently boomed as independent, savvy investors seek more ways to earn yield in response to historically low interest rates. The days of building wealth through savings accounts are over, prompting the rise of self-service investment services like Robinhood and Betterment, which allow investors more direct control over their financial futures. 

In particular, alternative investments have proven pivotal, with investors aiming to diversify their portfolios to include private assets like real estate, venture capital, or cryptocurrency, instead of focusing solely on the public markets. These assets, which have long been held by institutions and high-net-worths, are quickly becoming available to smaller investors via various online investment platforms and service providers. 

Dubbed ‘Zillow for investors,’ Vincent unifies the fragmented world of alternative investing into an easy-to-use search engine, making opportunities accessible for everyday investors. On Vincent, investors can browse, compare, and research hundreds of unique investment opportunities from partner platforms including Fundrise, Yieldstreet, StartEngine, Roofstock, Masterworks, and Otis. 

“Investment discovery for alternatives has been a pain point for investors,” says Vincent CEO Eric Cantor. “On Vincent, we’re seeing the typical investor review 25 investment offers, while 70 percent of investors search for at least two asset types.” 

Vincent, which has been in private beta since July 2020, currently indexes nearly $2 billion of available investments across asset classes including venture capital, real estate, private equity, private credit, art, collectibles, and more. To date, more than 100,000 investment searches have been conducted by 15,000 unique investors.  

Vincent is the brainchild of Indiegogo founder Slava Rubin and former Indiegogo investing lead Evan Cohen. They are joined by fintech entrepreneur Eric Cantor and technology lead Ross Cohen, former head of engineering at Mirror, which sold to Lululemon for $500 million. 

“With the alternative investment market set to grow from $9 to $14 trillion in the next five years, Vincent was the right next step on my journey to democratize access to investing,” says Rubin, Vincent co-founder and Executive Chairman. 

The trend has not gone unnoticed, as venture capitalists have poured hundreds of millions of dollars into the growing alternative investment ecosystem. The platforms on Vincent benefit from the 2012 JOBS act rules, which opened the door for general solicitation and crowdfunding online. This past month, the SEC announced expansions to those rules, which will lead to further growth and increase the availability of online alternative investment opportunities. 

Using Vincent’s search engine, investors can create custom searches tailored to fit their interests and portfolio needs. Investors can search across various platforms and filter by asset class, investment minimums, liquidity terms, and even potential return. Vincent’s backend aggregates the data, making it easy for investors to review and connect with the right investment platforms with just a few clicks. 

In conjunction with its formal launch, Vincent announced a $2 million round of capital to support its growth. Investors include Uncommon Denominator, humbition, ERA, and The Fund, as well as several strategic angels, including Jeff Fagnan (Accomplice, AngelList), Alap Shah (Sentieo), and Lazslo Bock (Google, Humu). 

About Vincent
Vincent is the most comprehensive search engine for alternative asset investing. Headquartered in New York City, we aggregate thousands of investment opportunities across real estate, venture capital, private equity, debt, art, collectibles, and more into one easy-to-navigate website. Through Vincent, investors gain unprecedented access to new, quality investment opportunities and research, entirely for free. Since July 2020, we have serviced over 100,000 investment searches by more than 15,000 unique investors. For more information, please visit www.withvincent.com and @DiscoverVincent.

[email protected]

San Diego, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) — New data on Biotheranostics’ Breast Cancer Index test will be highlighted at the 43rd annual San Antonio Breast Cancer Symposium (SABCS) being held virtually from December 8-12, 2020. Breast Cancer Index continues to expand on a strong body of evidence as the only commercially available genomic assay to help inform the decision of extended endocrine therapy based on prediction of benefit for HR+ early stage breast cancer patients.

Results from three independent studies will be presented during this week’s meeting, including data that will be featured in a Spotlight Session Wednesday, December 9th, as well as the General Session Friday morning, December 11th. Presentations include new results from the IDEAL study, which validated BCI as the first commercially available test with the ability to predict benefit from extended AI therapy in post-menopausal patients who have already been treated with 5 years of AI therapy. In addition, a correlative biomarker study in the Trans-aTTom cohort will also be presented. The collective evidence supports routine clinical use of BCI for HR+ early stage breast cancer as a predictive biomarker of benefit and outcome from extended endocrine therapy that is agnostic to tamoxifen and/or AI treatment.  

General Session GS4-09; Fri 12/11 10:45am CST

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine benefit: a Trans-aTTom Study. Sgroi et al

Spotlight Session PD2-11; Wed. 12/9 5:15-6:30pm CST

Breast Cancer Index is a molecular signature of endocrine responsiveness that determines extended endocrine benefit independent of prognostic risk. Liefers et al

Poster Session PS17-32; Wed. 12/9 8:00am CST  

Characterization of HOXB13-induced estrogen receptor reprogramming in breast cancer cells. Treuner et al

Catherine Schnabel, Biotheranostics’ Chief Scientific Officer states, “As SABCS is the leading breast oncology meeting that presents practice-changing advancements in the field, it is an important milestone to have data from both the Trans-aTTom and IDEAL studies, which strengthen the clinical utility and distinct ability of BCI to predict which patients will benefit from extended endocrine therapy, featured this year.”

Don Hardison, Biotheranostics’ President and CEO adds, “We continue to add to the strength of our evidence with the singular goal of making Breast Cancer Index standard of care for all HR+ early stage breast cancer patients. We believe every woman should be offered a test that helps guide the joint decision related to extended endocrine therapy.”

About Breast Cancer Index

Breast Cancer Index is a molecular, gene expression-based test uniquely positioned to provide information to help physicians individualize treatment decisions for patients with early stage, HR+ breast cancer. This breakthrough test helps oncologists and patients navigate the difficult trade-off between taking steps to prevent recurrence of their disease and facing significant side effects and safety challenges related to unnecessary treatment. Breast Cancer Index holds guidelines designation from the American Joint Committee on Cancer for cancer staging based on molecular profile; ASCO, NCCN, European Group on Tumor Markers (EGTM), and St. Gallen to inform the chemotherapy decision; and ASCO and EGTM to inform the extended endocrine treatment dilemma. It is the only validated, commercially available test that provides risk of overall and late distant recurrence and predicts the likelihood of benefit from extended endocrine therapy. For more information, visit www.breastcancerindex.com.

 
About Biotheranostics

Biotheranostics, Inc. operates a CLIA-certified and CAP-accredited diagnostic laboratory in San Diego, California. Biotheranostics, Inc., is a leading healthcare provider in the oncology field assisting physicians in the treatment of cancer patients. Its suite of proprietary molecular diagnostic tests provides important information to physicians to tailor treatment to individual patients. The company’s Breast Cancer Index and CancerTYPE ID^® tests address a variety of unmet medical needs in the management of cancer patients, and extensive clinical studies have confirmed the accuracy, clinical validity, clinical utility, and cost-effectiveness of the tests. Learn more at www.biotheranostics.com.

Lisa Whitmyer
Biotheranostics, Inc.
216-513-7808
[email protected]

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Pasit Phiasivongsa, Ph.D., as senior vice president, pharmaceutical development. Dr. Phiasivongsa brings more than 20 years of experience in the biopharmaceutical industry overseeing manufacturing processes for novel medicines.

“I am delighted to welcome Pasit to the leadership team at Kronos Bio,” said Norbert Bischofberger, Ph.D., president and CEO. “Pasit has a proven track record of success in devising and executing accelerated manufacturing strategies throughout a product’s life cycle, from clinical development to commercial supply. He will be an instrumental member of our team as we prepare to begin clinical testing of KB-0742, our CKD9 inhibitor, and initiate our planned pivotal trial for entospletinib, our SYK inhibitor, next year.”

Dr. Phiasivongsa has extensive experience overseeing chemistry, manufacturing and controls (CMC) development strategies and advancing programs from proof-of-concept validation through commercial production. He most recently served as senior vice president, technical operations, at Principia Biopharma, a Sanofi company, where he led all CMC development, manufacturing and supply chain-related activities and built the company’s technical operations organization. Prior to Principia, he was vice president, pharmaceutical development, at Tobira Therapeutics (acquired by Allergan), where he was responsible for CMC, technical operations and supply chain activities, and led the intellectual property strategy and development for the company’s core assets. Earlier in his career, he held positions in drug discovery, development and manufacturing at Dynavax Technologies; Onyx Pharmaceuticals, an Amgen subsidiary; Proteolix, Inc. (acquired by Onyx Pharmaceuticals); Astex Pharmaceuticals (formerly SuperGen, Inc.); and Optimer Pharmaceuticals. He began his career as a research assistant at Cell Pathways, Inc.

“I am thrilled to be joining Kronos Bio at this transformative time when the company will soon commence clinical testing of two investigational therapies,” said Dr. Phiasivongsa. “I look forward to working with the team to advance our current programs and guide pharmaceutical development strategy for the future. Together, we have an exceptional opportunity to improve patients’ lives.”

Dr. Phiasivongsa holds a B.S. in biochemistry and a Ph.D. in pharmaceutical and chemical sciences from the University of the Pacific. He is listed on 26 U.S.-issued patents and more than 30 patent applications.

About Kronos Bio, Inc.

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

Forward-Looking Statements

Statements in this press release that are not statements of historical fact are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release, in some cases, uses terms such as “expects,” “planned,” “prepare,” “begin,” “initiate,” “commence,” “look forward,” “guide,” “intends,” “will,” “should,” “seek” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding Kronos Bio’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Kronos Bio’s plans to begin a Phase 1/2 clinical trial of KB-0742 in patients with advanced solid tumors and the expected timing thereof; the design of such planned Phase 1/2 clinical trial, including to establish clinical proof of concept to enable potential further development; and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: whether Kronos Bio will be able to initiate or complete the Phase 1/2 clinical trial of KB-0742 and the planned clinical trial of ENTO on the timeline expected, if at all, including due to risks associated with the COVID-19 pandemic and risks inherent in the clinical development of novel therapeutics; risks related to Kronos Bio’s lack of experience as a company in conducting clinical trials; the risk that results of preclinical studies and early clinical trials are not necessarily predictive of future results; the risk that due to the relatively small number of patients that Kronos Bio plans to dose in the planned Phase 1/2 KB-0742 clinical trial, the results from the planned Phase 1/2 clinical trial, once completed, may be less reliable than results achieved in larger clinical trials, which may hinder Kronos Bio’s efforts to further develop and obtain regulatory approval for KB-0742; and risks associated with the sufficiency of Kronos Bio’s cash resources and need for additional capital. These and other risks are described in greater detail in Kronos Bio’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 18, 2020. Any forward-looking statements that are made in this press release speak only as of the date of this press release and are based on management’s assumptions and estimates as of such date. Except as required by law, Kronos Bio assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:

Stephanie Yao
Executive Director, Investor Relations and Corporate Communications
650-525-6605
[email protected]

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) — Solar Senior Capital Ltd. (the “Company”) (NASDAQ: SUNS) declared a distribution of $0.10 per share for the month of December 2020. The distribution is payable on January 5, 2021 to stockholders of record as of December 22, 2020. The specific tax characteristics of the distribution will be reported to stockholders on Form 1099 after the end of the calendar year.

ABOUT SOLAR
SENIOR
CAPITAL LTD.

Solar Senior Capital Ltd. is a closed-end investment company that has elected to be treated as a business development company under the Investment Company Act of 1940. A specialty finance company with expertise in several niche markets, the Company generally invests directly and indirectly in leveraged, U. S. middle market companies primarily in the form of cash flow senior secured loans, including first lien loans, and asset-based loans collateralized on a first lien basis primarily by current assets.

FORWARD-LOOKING STATEMENTS

Statements included herein may constitute “forward-looking statements,” which relate to future events or our future performance or financial condition. These statements are not guarantees of future performance, condition or results and involve a number of risks and uncertainties, including the impact of COVID-19 and related changes in base interest rates and significant market volatility on our business, our portfolio companies, our industry and the global economy. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in our filings with the Securities and Exchange Commission. Solar Senior Capital Ltd. undertakes no duty to update any forward-looking statements made herein, unless required to do so by law.

Contact:
Solar Senior Capital Ltd.
Investor Relations
646-308-8770

VANCOUVER, British Columbia, Dec. 08, 2020 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”)(CSE: BIGG; OTCQB: BBKCF; WKN: A2PS9W), owner of Netcoins (Netcoins.ca) (“Netcoins”), the online cryptocurrency brokerage that makes it easy for Canadians to buy, sell, and understand cryptocurrency, and owner of Blockchain Intelligence Group (“BIG”), a leading developer of Blockchain technology search, risk-scoring and data analytics solutions, is pleased to announce that it has acquired 40 additional Bitcoins for long term treasury holding. BIGG purchased these Bitcoins for $24,854 CAD per BTC for a total of CAD $994,160.00.

This purchase, added to BIGG’s existing Bitcoin holdings, brings the treasury to ~189.5 Bitcoin, valued at CAD ~$4.65 million (USD ~$3.63 million) as of 4pm PST December 7th, 2020. BIGG believes strongly in the future of Bitcoin, its store of value capability, and its future valuation potential.

BIGG CEO, Mark Binns, remarks, “BIGG (formerly BIG Blockchain Intelligence Group) started accumulating Bitcoin as far back as 2015. Bitcoin has appreciated substantially as an asset class over 1, 2, 5 and 10 years horizons, and we believe the potential for impactful price appreciation is stronger today than ever. Institutional involvement and buying, and mainstream adoption, will continue to drive the price of Bitcoin as supply remains capped. We believe our Bitcoin holdings can act as self financing, over time, as we continue to expand our core crypto trading and blockchain forensic software businesses.”

On behalf of the Board

Mark Binns
CEO
[email protected]
T:+1.844.515.2646

About BIGG Digital Assets Inc.

BIGG Digital Assets Inc. (BIGG) believes the future of crypto is a safe, compliant, and regulated environment. BIGG invests in products and companies to support this vision. BIGG owns two operating companies: Netcoins (netcoins.ca) and Blockchain Intelligence Group (blockchaingroup.io).

Netcoins develops brokerage and exchange software to make the purchase and sale of cryptocurrency easily accessible to the mass consumer and investor with a focus on compliance and safety. Netcoins utilizes BitRank Verified^® software at the heart of its platform and facilitates crypto trading via a self-serve crypto brokerage portal at Netcoins.app.

Blockchain Intelligence Group (BIG) has developed a Blockchain-agnostic search and analytics engine, QLUE^TM, enabling Law Enforcement, RegTech, Regulators and Government Agencies to visually track, trace and monitor cryptocurrency transactions at a forensic level. Our commercial product, BitRank Verified^®, offers a “risk score” for cryptocurrencies, enabling RegTech, banks, ATMs, exchanges, and retailers to meet traditional regulatory/compliance requirements.

For more information and to register to BIGG’s mailing list, please visit our website at https://www.biggdigitalassets.com. Or visit SEDAR at www.sedar.com.

Forward-Looking Statements:

Certain statements in this release are forward-looking statements, which include completion of the search technology software and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific that contribute to the possibility that the predictions, estimates, forecasts, projections and other forward-looking statements will not occur. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, and other factors, many of which are beyond the control of BIGG. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. Undue reliance should not be placed on the forward-looking information because BIGG can give no assurance that they will prove to be correct. Important factors that could cause actual results to differ materially from BIGG’s expectations include, consumer sentiment towards BIGG’s products and Blockchain technology generally, technology failures, competition, and failure of counterparties to perform their contractual obligations.

The forward-looking statements contained in this press release are made as of the date of this press release. Except as required by law, BIGG disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, BIGG undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.

The CSE does not accept responsibility for the adequacy or accuracy of the content of this Press Release.

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) — NEOVOLTA INC. (OTCQB: NEOV) – NeoVolta, manufacturer of Smart Energy Storage Systems, has received a total of $902,000 in purchase orders from PMP Energy. The most recent is a reorder of $425,000. This purchase order is part of a three-year exclusive distribution agreement signed earlier in 2020. In exchange for a minimum of up to $15 million in purchase orders, PMP Energy will provide dealers with training and certification to install NeoVolta systems in homes and other locations. To date they have trained and certified installers in four states plus the territory of Puerto Rico.

This latest order follows an initial purchase order from PMP Energy for $473,000, which was announced on September 1. According to Dan Briggs, PMP Energy’s President and CEO, “This is the first reorder of what we expect to be monthly orders of this size or larger.”

The large orders from PMP Energy come at a time of growing demand for home energy storage. Despite the COVID-19 pandemic, the U.S. residential energy storage market recorded its second-best quarter ever during Q2 2020. Industry analysts predict that 2020 could double the home battery capacity installed in 2019.

The NeoVolta NV14 is one of the best-performing systems in this space, with a storage capacity of 14.4 kilowatt-hours and 7.7 kilowatts of continuous power discharge. That high storage capacity can be scaled up to 24.0 kWh with the optional NV24 add-on battery, without the expense of an additional inverter. All NeoVolta systems are engineered with advanced lithium iron phosphate chemistry, a safer and longer-lasting alternative to ordinary lithium ion.

For its superior performance and safe, long-lasting battery chemistry, the NV14 was named one of Solar Power World’s top storage products of 2019.

“PMP Energy has proven to be an outstanding distributor,” said NeoVolta CEO Brent Willson. “They have established a strong installer network and formalized a comprehensive training program for new and existing installers. PMP Energy is on the cutting edge of the Energy Storage space when it comes to developing distribution capabilities often overlooked by our competitors.”

About NeoVolta – NeoVolta designs, develops and manufactures utility-bill reducing residential energy storage batteries capable of powering your home even when the grid goes down. With a focus on safer Lithium-Iron Phosphate chemistry, the NV14 is equipped with a solar re chargeable 14.4 kWh battery, a 7,680-Watt inverter and a web-based energy management system with 24/7 monitoring. By storing energy instead of sending it back to the grid, consumers can protect themselves against blackouts, avoid expensive peak demand electricity rates charged by utility companies when solar panels aren’t producing, and get one step closer to grid independence.

For more information visit: http://www.NeoVolta.com email us: [email protected] or call us: 858-239-2029

Forward-Looking Statements: Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of PMP Energy to continue to provide reorders and orders of the size discussed in the release, the future performance, reliability and safety of NeoVolta’s NV14 storage system and the ability of the NV14 to be successfully integrated with residential backup generators. Although NeoVolta believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. NeoVolta has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the section Item 1. Business – Risk Factors of NeoVolta’s Form 1-K filing filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in its other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. NeoVolta undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

MORRISTOWN, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) — Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – will present three posters at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition, being held virtually December 6-10, 2020.

The following poster presentations will be available on-demand at the ASHP Midyear Meeting and Exhibition website on Tuesday, December 8, 2020, 3:00 – 4:30 pm EST:

• Current Use Patterns for Ketorolac Intravenous Bolus for Post-Operative Pain in Inpatient Settings – Results of a Chart Audit in 119 Hospitals Across the United States
  
  Presenter: Ilona Steigerwald, Chief Medical Officer, Neumentum, Inc.
  Poster ID: 112

• Final Results of a Randomized, Controlled Trial in Healthy Volunteers with NTM-001 (Novel Formulation of Ketorolac for Continuous Intravenous Infusion) Meet Targets of Model-Informed Development
  
  Presenter: Ilona Steigerwald, Chief Medical Officer, Neumentum, Inc.
  Poster ID: 113

• Final Study Results in Elderly Subjects with No, Mild and Moderate Renal Impairment Meet Targets of Model-Informed Development for NTM-001 (Ketorolac for Continuous Intravenous Infusion)
  
  Presenter: Ilona Steigerwald, Chief Medical Officer, Neumentum, Inc.
  Poster ID: 114

The data to be presented include the final study results from four cohorts of a randomized, controlled clinical trial evaluating NTM-001, Neumentum’s novel, alcohol-free 24-hour continuous infusion formulation of the well-established potent NSAID analgesic ketorolac tromethamine. Neumentum is developing NTM-001 to potentially be a suitable alternative to opioids in the management of postoperative pain including in elderly and/or renally impaired patients.

“We are incredibly encouraged by the results from this first-in-man study evaluating NTM-001,” said Scott Shively, Chief Executive officer of Neumentum. “The data presented in these posters will spur us to conduct further research in the pursuit of safe and effective pain management without the risks for abuse and misuse that come with opioids.”

“This data underscore our commitment to validating NTM-001 with the very best science,” said Dr. Joseph Pergolizzi, Executive Chairman of Neumentum. “We look forward to the path ahead and to further validating these findings to address the global unmet needs of chronic and acute pain.”

Earlier this year, Neumentum shared a corporate update on the progression of its pipeline of non-opioid analgesic programs, which outlined the regulatory path forward for NTM-001, and the company’s intention to initiate a Phase 3 pivotal, post-bunionectomy efficacy study following the completion of its next round of equity financing.

About Neumentum: Addressing a National Health Emergency

Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company with product candidates that have the potential to provide the benefits of safe and effective pain management without the risks of abuse, misuse and diversion seen with opioids, or opioid-induced side effects including potentially life-threatening respiratory depression.

Opioid use is considered a critical public health concern in the US. In 2018, 9.9 million people over age of 12 reported misusing prescription opioid pain relievers¹, and opioids were involved in 46,802 overdose deaths.² Opioids also account for over 305,000 emergency department visits annually for non-fatal overdoses.³ Despite these staggering statistics, and the frequently reported opioid-induced side effects such as nausea, vomiting, constipation and somnolence, 168 million prescriptions – over 51 prescriptions per 100 Americans – were written for opioids in 2018.⁴

Neumentum has two lead product candidates being developed to directly help address the opioid crisis. NTM-006, a Phase 2 novel oral analgesic with a target indication for moderate to severe chronic pain, was licensed in late 2019 from Janssen Pharmaceuticals NV and McNeil Consumer Pharmaceuticals Co., both part of the Johnson & Johnson Family of Companies. NTM-001 is a Phase 3-ready IV formulation of Toradol (ketorolac), with recent Phase I results showing that it may provide consistent, steady blood plasma levels of ketorolac over 24 hours and durable analgesic effect. This Phase I study is part of a program supporting what has the potential to be the first-ever NSAID approved for continuous infusion.

Neumentum is led by a world-wide executive team of biotech and pharmaceutical industry leaders who have extensive experience in pain and neurology, from drug development through commercialization. For more information, visit www.Neumentum.com.

INVESTOR CONTACT:

Scott Shively
CEO & Co-founder
[email protected]
(833) NEUPAIN

MEDIA CONTACT:

Megan Kernan
Westwicke, an ICR company
[email protected]
(952) 221-2096

[1] SAMSHA, Key Substance Use and Mental Health Indicators in the US: Results from the 2018 National Survey on Drug Use and Health. P13, Fig 10.
[2] Wilson N, Kariisa M, Seth P, Smith H IV, Davis NL. MMWR Morb Mortal Wkly Rep 2020; 69:290–297
[3] Vivolo-Kantor AM, Hoots BE, Scholl L, et al. MMWR Morb Mortal Wkly Rep 2020;69:371–376
[4] www.cdc.gov/drugoverdose/maps/rxrate-maps.html, accessed 16 Jul 2020